|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date28 Sep 2000 |
The Effect of Vaginal Mifepristone on Reduction of Uterine Fibroids Size and the Symptoms Associated With the Fibroids - Pilot Study (Phase IIa)
The purpose of this study is to evaluate the effect of daily dosage of vaginally mifepristone on reduction of uterine fibroids size and the symptoms associated with uterine fibroids.
100 Clinical Results associated with BioPro Medical Ltd
0 Patents (Medical) associated with BioPro Medical Ltd
100 Deals associated with BioPro Medical Ltd
100 Translational Medicine associated with BioPro Medical Ltd